Chiron Dealt Blow Over Cystic Fibrosis Treatment

Law360, New York (May 17, 2006, 12:00 AM EDT) -- In a setback for biopharmaceutical company Chiron Corp., a federal judge has ruled that the company’s medical-method patent covering a drug-device combination used by cystic fibrosis victims cannot be used to bar use of the treatment in lower concentrations.

The patent at issue in the case, U.S. Patent No. 6,890,907, covers a method of treating lung infections by using certain concentrations of liquid tobramycin with high-efficiency nebulizers.

The method is aimed at treating patients suffering from cystic fibrosis, a debilitating disease that manifests in early childhood...
To view the full article, register now.